The Live Surgery Case was performed by Dr. Anne Schuckman, Urologist from University of Southern California (USC, Los Angeles, CA). The discussion on clinical benefits of Cysview Blue light Cystoscopy at the plenary sessions were led by Dr. Sia Daneshmand, (USC), Dr. Harry W. Herr (Memorial Sloan Kettering Cancer Center, NY) and Dr. Mark Soloway (University of Miami, FL).
Blue Light Cystoscopy with Hexvix/Cysview is an advancement in detection and management of non-muscle invasive bladder cancer (NMIBC). The medical benefits and health economic benefits provided by Hexvix/Cysview have been well documented and are currently included in several national and international guidelines on bladder cancer. Hexvix/Cysview has been used in 265,000 procedures to date, with consistent evidence that it improves detection and management of bladder cancer compared to White Light Cystoscopy (WLC) alone.
Bladder cancer affects 577,000 people in the United States, with 74,690 newly diagnosed patients every year. Approximately 16,000 patients will die from the disease in 2015 mainly due to recurrence of the cancer. The live surgery event at the AUA meeting further reflects in a real life setting the clinical evidence and value of supporting widespread adoption of Blue Light Cystocopy with Cysview.
*Cysview® is tradename in US, Hexvix® in Europe